Abstract
Background
N‐docosahexaenoyl ethanolamine (DHEA; also known as synaptamide) binds to both the CB1 and CB2 cannabinoid receptors and has anti‐inflammatory properties in vitro. However, the in vivo effects of DHEA are unknown. Therefore, this study was designed to understand the effects of DHEA in models of pain and inflammation in mice.
Methods
The intraplantar formaldehyde assay, hot water tail withdrawal assay and hotplate model were used to assess the antinociceptive properties of DHEA in mice. The mechanism of action was studied by antagonising the cannabinoid receptors, transient receptor potential vanilloid 1 (TRPV1) ion channel, peroxisome proliferator‐activated receptors (PPARs) and G‐protein receptor 55 (GPR55).
Results
DHEA (2‐10 mg/kg) reduced the levels of nociceptive and inflammatory pain‐related behaviour over 60 min in the intraplantar formaldehyde assay via both intraperitoneal and local intraplantar administration. The area under the curve analysis showed the overall antinociceptive effects of DHEA (10 mg/kg) were not modulated by pre‐treatment with antagonists for the cannabinoid receptors, TRPV1 ion channel, PPARα, PPARγ, or GPR55. However, the time‐course analysis showed that within the early inflammatory phase, antagonism of the CB2 receptor, PPARα and PPARγ led to a partial reversal of the antinociceptive effects of DHEA. In the hot water tail withdrawal and hotplate models of thermal nociception, DHEA (2‐10 mg/kg) did not have any antinociceptive effects.
Conclusions
DHEA reduced the level of formaldehyde‐induced nociceptive and inflammatory pain‐related behaviour; however, was not active in thermal nociceptive models. This study highlights the potential of DHEA for the treatment of acute inflammatory pain.
from Wiley: European Journal of Pain: Table of Contents https://ift.tt/34CQeNh
via IFTTT
No comments:
Post a Comment